Scotiabank raised the firm’s price target on Alnylam (ALNY) to $450 from $342 and keeps an Outperform rating on the shares. The company’s beat and raise underscores the “stellar” early launch momentum of Amvuttra in transthyretin amyloid cardiomyopathy, the analyst tells investors. The firm is increasing its price target to reflect updated expectations for Amvuttra’s growth trajectory.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target raised to $424 from $370 at Raymond James
- Alnylam price target raised to $449 from $304 at Piper Sandler
- Alnylam price target raised to $550 from $403 at UBS
- Alnylam price target raised to $415 from $390 at Canaccord
- Alnylam Pharma: Strong Financials and Strategic Advancements Drive Buy Rating